DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of thermostabilized viral vaccines from the Bill & Melinda Gates Foundation.

DelSiTechTMSilica Matrix is an advanced, sustained and controlled release delivery technology for administration of injectable, implant and topical eye drop dosage forms. One important feature of DelSiTech’s technology is the ability to confer thermostability to viruses over long periods of time, over years.

“To ensure the optimal potency of vaccines, storage conditions need careful attention and maintenance of the cold chain is especially important in developing countries, where outdoor temperatures can easily exceed 40°C,” said Dr. Lasse Leino, CEO of DelSiTech. “We are delighted and honoured to receive funding from the Bill & Melinda Gates Foundation for such an exciting and critical program.”